Nabriva Therapeutics AG (NASDAQ:NBRV) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 04:30 pm ET
Ladies and gentlemen, thank you for standing by. And welcome to the Nabriva Therapeutics Second Quarter 2020 Financial Results Call. [Operator Instructions] After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the call over to Mr. Gary Sender, Nabriva's Chief Financial Officer. Please go ahead, sir.
Thank you, and good afternoon, everyone. Welcome to Nabriva's conference call and webcast where we will discuss the second quarter 2020 earnings and also provide a business update. Similar to last quarter's earnings call, the slides for today's presentation are posted on the company's website, www.nabriva.com, and can be found under the Investors tab in the Events and Presentations section. We recommend that you refer to the presentation, as we will be using those slides for today's discussion.
Before we begin, on Slide 2, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call.
We will undertake no obligation to revise or publicly release the results of any revisions to these forward-looking statements, in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and our other periodic reports on Forms 10-Q and 8-K filed with the SEC.
Moving to Slide 3. I'd like to share the agenda for today. Ted Schroeder, Nabriva's CEO, will start with a business update. Francesco Maria Lavino, Nabriva's Chief Commercial Officer, will present an overview on the commercial highlights and the strategy for the relaunch of XENLETA and SIVEXTRO following the recent transaction with Merck.
Then, Dr. Jennifer Schranz, our Chief Medical Officer, will discuss the exploration of expanded studies with XENLETA. I will provide a financial review, and Ted will come back with some summary comments and lead a Q&A session. In addition to Ted, Jennifer and Francesco, joining us on the call for the Q&A session is Steve Gelone, our President and Chief Operating Officer.
I would now like to turn the call over to our Chief Executive Officer, Ted Schroeder.
Thank you, Gary, and thanks to everyone for joining our call this afternoon. Let's start on Slide 5. Earlier this year, the management team laid out the company's 2020 strategic priorities. These priorities included the shift to commercialization for XENLETA to the community; the active pursuit of business development and licensing opportunities, with a focus on community-based products; obtaining the approval of XENLETA in Europe and Canada; preparing for the launch of CONTEPO; and the thoughtful management of Nabriva's balance sheet and expenses.
Nabriva has spent the last several months planning, preparing and executing on our strategic plan to shift our commercial focus to the